B+
Bull case
25%
Probability
Target price
$30.00
+42.1% vs current
OPCH
Option Care HealthDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-11
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$24.00
+13.7% vs current
B-
Bear case
25%
Probability
Target price
$17.00
-19.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-06
Recent news sentiment (30D)
-29.3
Negative
Company
-
Unavailable
Macro
-29.3
Negative
Pulse
-
Unavailable
Sentiment proxy
+60.7
Score
AI commentary
Primary-source evidence points to a cautious rather than broken thesis: Q1 exposed a real revenue-growth problem, and recent headlines were negative, including a selloff framed around disappointing growth. The $21.30 anchor implies the market has already repriced materially lower after the April 30 update, but fresh analyst revision coverage in the packet is limited, so confidence should stay moderate-low until a post-cut estimate reset and another operating datapoint arrive.
RankAlpha Sentiment Codex - 2026-05-06
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-08catalystChief Growth Officer departure raises execution sensitivityMedium impact
The company disclosed that Chief Growth Officer Christopher L. Grashoff will depart effective May 8, 2026, immediately after a quarter where management said it was not satisfied with revenue growth momentum. That does not change the franchise by itself, but it raises near-term scrutiny on commercial execution and referral growth. [#8-K-2026-05-05]
2026-08-04eventQ1 growth reset and lowered 2026 revenue outlookHigh impact
Q1 net revenue rose 1.3% to $1.351B, but gross profit fell 0.4% and management said chronic inflammatory disease dynamics, patient attrition, and unfavorable therapy mix should reduce 2026 gross profit by about $55M; full-year revenue guidance was reset to $5.675B-$5.775B. The next debate is whether acute growth and corrective actions can offset chronic mix pressure. [#10-Q-2026-04-30]
2026-12-31catalystEarnings resilience and liquidity partially offset top-line pressureHigh impact
Despite the revenue reset, management maintained full-year adjusted EPS guidance of $1.82-$1.92 and adjusted EBITDA guidance of $480M-$505M, while the revolver was expanded to $850M and the board-authorized repurchase capacity remains large. That supports downside cushioning if execution stabilizes. [#10-Q-2026-04-30]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-06 • Updated nightlySource: Internal modelMethodology